| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 75.62M |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 72K | 537K | 0 | 0 | 6.22M | 8.12M |
| COGS % of Revenue | - | - | - | - | - | 0.11% |
| Gross Profit | -72K | -537K | 0 | 0 | -6.22M | 67.5M |
| Gross Margin % | - | - | - | - | - | 0.89% |
| Gross Profit Growth % | - | -6.46% | 1% | - | - | 11.85% |
| Operating Expenses | 7.99M | 27.47M | 72.88M | 112.38M | 137.09M | 148.61M |
| OpEx % of Revenue | - | - | - | - | - | 1.97% |
| Selling, General & Admin | 644K | 4M | 15.73M | 27.32M | 32.04M | 35.17M |
| SG&A % of Revenue | - | - | - | - | - | 0.47% |
| Research & Development | 7.35M | 23.47M | 57.16M | 85.06M | 105.05M | 121.56M |
| R&D % of Revenue | - | - | - | - | - | 1.61% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -8.12M |
| Operating Income | -7.99M | -28.01M | -72.88M | -112.38M | -143.31M | -81.11M |
| Operating Margin % | - | - | - | - | - | -1.07% |
| Operating Income Growth % | - | -2.5% | -1.6% | -0.54% | -0.28% | 0.43% |
| EBITDA | -7.92M | -27.47M | -70.75M | -108.64M | -137.09M | -72.99M |
| EBITDA Margin % | - | - | - | - | - | -0.97% |
| EBITDA Growth % | - | -2.47% | -1.58% | -0.54% | -0.26% | 0.47% |
| D&A (Non-Cash Add-back) | 72K | 537K | 2.13M | 3.75M | 6.22M | 8.12M |
| EBIT | -7.74M | -28.01M | -72.88M | -112.38M | -143.31M | -81.11M |
| Net Interest Income | -988 | 9K | 46K | 0 | 9.33M | 10.57M |
| Interest Income | 12 | 9K | 46K | 3.76M | 9.33M | 10.57M |
| Interest Expense | 1K | 0 | 0 | 3.76M | 0 | 0 |
| Other Income/Expense | 254K | -7.87M | -1.08M | 3.88M | 8.3M | 10.98M |
| Pretax Income | -7.74M | -35.88M | -73.96M | -108.5M | -135.01M | -70.13M |
| Pretax Margin % | - | - | - | - | - | -0.93% |
| Income Tax | 0 | 0 | 0 | 0 | 338K | 2.57M |
| Effective Tax Rate % | 1.04% | 1% | 1% | 1% | 1% | 1.04% |
| Net Income | -8.02M | -35.88M | -73.96M | -108.5M | -135.35M | -72.7M |
| Net Margin % | - | - | - | - | - | -0.96% |
| Net Income Growth % | - | -3.48% | -1.06% | -0.47% | -0.25% | 0.46% |
| Net Income (Continuing) | -7.74M | -35.88M | -73.96M | -108.5M | -135.35M | -72.7M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.18 | -0.82 | -1.59 | -2.30 | -2.63 | -0.98 |
| EPS Growth % | - | -3.56% | -0.94% | -0.45% | -0.14% | 0.63% |
| EPS (Basic) | -0.18 | -0.82 | -1.59 | -2.30 | -2.63 | -0.98 |
| Diluted Shares Outstanding | 44M | 44M | 46.54M | 47.23M | 51.4M | 73.91M |
| Basic Shares Outstanding | 44M | 44M | 46.54M | 47.23M | 51.4M | 73.91M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 9.76M | 43.59M | 348.67M | 275.89M | 236.21M | 377.44M |
| Cash & Short-Term Investments | 6M | 41.7M | 346.07M | 262.83M | 232.41M | 372.15M |
| Cash Only | 6M | 41.7M | 346.07M | 54.91M | 128.1M | 224.25M |
| Short-Term Investments | 0 | 0 | 0 | 207.91M | 104.31M | 147.9M |
| Accounts Receivable | 0 | 0 | 0 | 7.66M | 505K | 173K |
| Days Sales Outstanding | - | - | - | - | - | 0.83 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 3.25M | 100K | 0 | 5.4M | 3.29M | 5.12M |
| Total Non-Current Assets | 1.33M | 5.79M | 17.66M | 66.5M | 67.54M | 61.29M |
| Property, Plant & Equipment | 1.33M | 4.62M | 12.32M | 61.91M | 62.61M | 56.31M |
| Fixed Asset Turnover | - | - | - | - | - | 1.34x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 1.16M | 5.34M | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 4.6M | 4.93M | 4.98M |
| Total Assets | 11.09M | 49.38M | 366.33M | 342.39M | 303.75M | 438.73M |
| Asset Turnover | - | - | - | - | - | 0.17x |
| Asset Growth % | - | 3.45% | 6.42% | -0.07% | -0.11% | 0.44% |
| Total Current Liabilities | 4.29M | 29.27M | 16.64M | 25.57M | 46.59M | 156.95M |
| Accounts Payable | 3.19M | 7.07M | 6.56M | 7.86M | 11.15M | 17.21M |
| Days Payables Outstanding | 16.2K | 4.8K | - | - | 654.21 | 773.73 |
| Short-Term Debt | 750K | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 1000K | 1000K |
| Other Current Liabilities | 0 | 21.08M | 840K | 10.64M | 9.26M | 11.57M |
| Current Ratio | 2.27x | 1.49x | 20.96x | 10.79x | 5.07x | 2.40x |
| Quick Ratio | 2.27x | 1.49x | 20.96x | 10.79x | 5.07x | 2.40x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 18.95M | 68.83M | 2.18M | 45.41M | 77.91M | 58.85M |
| Long-Term Debt | 0 | 67.76M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 43.87M | 42.88M | 39M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 18.95M | 0 | 2.18M | 1.53M | 2.71M | 3.7M |
| Total Liabilities | 23.24M | 98.11M | 18.81M | 70.98M | 124.5M | 215.8M |
| Total Debt | 750K | 67.76M | 0 | 47M | 46.04M | 42.72M |
| Net Debt | -5.25M | 26.07M | -346.07M | -7.91M | -82.06M | -181.54M |
| Debt / Equity | - | - | - | 0.17x | 0.26x | 0.19x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -7994.00x | - | - | -29.86x | - | - |
| Total Equity | -12.15M | -48.73M | 347.51M | 271.41M | 179.25M | 222.94M |
| Equity Growth % | - | -3.01% | 8.13% | -0.22% | -0.34% | 0.24% |
| Book Value per Share | -0.28 | -1.11 | 7.47 | 5.75 | 3.49 | 3.02 |
| Total Shareholders' Equity | -12.15M | -48.73M | 347.51M | 271.41M | 179.25M | 222.94M |
| Common Stock | 50K | 1K | 5K | 5K | 5K | 6K |
| Retained Earnings | -12.2M | -48.08M | -122.03M | -230.54M | -365.89M | -438.59M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -1.06M | -2.02M | -1.75M | -2.72M | -3.36M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -6.17M | -23.05M | -59.36M | -92.47M | -43.8M | 42M |
| Operating CF Margin % | - | - | - | - | - | 0.56% |
| Operating CF Growth % | - | -2.73% | -1.58% | -0.56% | 0.53% | 1.96% |
| Net Income | -7.74M | -35.88M | -73.96M | -108.5M | -135.35M | -72.7M |
| Depreciation & Amortization | 72K | 537K | 2.13M | 3.75M | 6.22M | 8.12M |
| Stock-Based Compensation | 0 | 0 | 5.2M | 11.66M | 16.67M | 18.13M |
| Deferred Taxes | 0 | 0 | 17K | 0 | 0 | 0 |
| Other Non-Cash Items | -276K | 8.03M | 960K | 2.76M | -3.81M | -2.95M |
| Working Capital Changes | 1.77M | 4.25M | 6.29M | -2.13M | 72.47M | 91.4M |
| Change in Receivables | 0 | 0 | 0 | -187 | 1.9M | 332K |
| Change in Inventory | 0 | 0 | 0 | 187 | 0 | 0 |
| Change in Payables | 2.86M | 3.44M | -706K | -744K | 5.76M | 6.25M |
| Cash from Investing | -1.39M | -3.39M | -9.65M | -219.22M | 88.8M | -44.45M |
| Capital Expenditures | -1.39M | -3.39M | -9.73M | -12.91M | -19.04M | -3.99M |
| CapEx % of Revenue | - | - | - | - | - | 0.05% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 15M | 60.06M | 377.56M | 20.47M | 27.49M | 98.89M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 0 | 0 | -3.19M | 411K | 0 | 98.59M |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -7.56M | -26.44M | -69.09M | -105.38M | -62.84M | 38.01M |
| FCF Margin % | - | - | - | - | - | 0.5% |
| FCF Growth % | - | -2.5% | -1.61% | -0.53% | 0.4% | 1.6% |
| FCF per Share | -0.17 | -0.60 | -1.48 | -2.23 | -1.22 | 0.51 |
| FCF Conversion (FCF/Net Income) | 0.77x | 0.64x | 0.80x | 0.85x | 0.32x | -0.58x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -49.51% | -35.06% | -60.07% | -36.15% |
| Return on Invested Capital (ROIC) | - | - | - | -63.63% | -59.6% | -87.79% |
| Gross Margin | - | - | - | - | - | 89.26% |
| Net Margin | - | - | - | - | - | -96.14% |
| Debt / Equity | - | - | - | 0.17x | 0.26x | 0.19x |
| Interest Coverage | -7994.00x | - | - | -29.86x | - | - |
| FCF Conversion | 0.77x | 0.64x | 0.80x | 0.85x | 0.32x | -0.58x |
Monte Rosa Therapeutics, Inc. (GLUE) reported $181.5M in revenue for fiscal year 2024.
Monte Rosa Therapeutics, Inc. (GLUE) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Monte Rosa Therapeutics, Inc. (GLUE) is profitable, generating $20.9M in net income for fiscal year 2024 (-96.1% net margin).
Monte Rosa Therapeutics, Inc. (GLUE) has a return on equity (ROE) of -36.2%. Negative ROE indicates the company is unprofitable.
Monte Rosa Therapeutics, Inc. (GLUE) generated $145.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.